209 Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.

208 An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse.

207 On-demand manufacturing of clinical-quality biopharmaceuticals.

206 Amycomicin is a potent and specific antibiotic discovered with a targeted interaction screen.

205 Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections.

204 Optimized arylomycins are a new class of Gram-negative antibiotics.

203 A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

202 Suppression of Staphylococcus aureus virulence by a small-molecule compound.

201 Species-specific activity of antibacterial drug combinations

200 A new class of synthetic retinoid antibiotics effective against bacterial persisters.

199 Digitization of multistep organic synthesis in reactionware for on-demand pharmaceuticals.

198 The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms.

197 A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models.

196 Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics.

195 Molecular basis of USP7 inhibition by selective small-molecule inhibitors.

194 Chemical synthesis yields gram quantities of a scarce compound under study for treating HIV, cancer, and Alzheimer’s disease.

193 Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

192 Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents.

191 Plasmonic silver nanoshells for drug and metabolite detection.

190 Synergy of synthesis, computation and NMR reveals correct baulamycin structures.

Free Images for Presentation: sunipix SUNIPIX